Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
--------
Question: Biotechnology company Alkermes said earlier in the day that  it expected Lilly to drop out of their program to develop an  inhaled insulin treatment for diabetes, sending Alkermes shares  down more than 9 percent. Lilly’s decision marks the third setback in recent months  for inhaled insulin formulations, once deemed potential  blockbuster products because of their greater convenience than  standard injectable insulin. Cambridge, Massachusetts-based Alkermes, which makes the  alcohol addiction drug Vivitrol, said Lilly has the right to  terminate its license to the inhaled treatment, Air Insulin, at  its discretion. “While Lilly may elect not to commercialize Air Insulin,  Alkermes believes that the phase 3 safety and efficacy trials  should be completed,” Alkermes said in a statement. After Lilly’s announcement, the company said it was  evaluating the impact of the termination, which will become  effective in 90 days. Indianapolis-based Lilly said its decision was not due to  safety concerns, “but rather was a result of increasing  uncertainties in the regulatory environment, and a thorough  evaluation of the evolving commercial and clinical potential of  the product compared to existing medical therapies.”    Lilly Chief Operating Officer John Lechleiter said in a  statement that the company is beginning the process of halting  ongoing clinical studies. Lilly said it will record a first-quarter 2008 charge of  around $90 million to $120 million, or 5 cents to 7 cents per  share. The company said its adjusted earnings per share outlook  remains unchanged at $3.85 to $4.00, while net earnings will  range from $3.73 to $3.90. Lilly’s action comes just five months after Pfizer Inc  abandoned Exubera, the first approved inhaled form of insulin,  and returned rights to the product to longtime partner Nektar  Therapeutics. Exubera had dismal sales because patients were turned off  by the clumsy device used to administer the powdered insulin  and because doctors were concerned by the drug’s tendency to  slightly impair lung function. Alkermes Chairman Richard Pops, in an interview with  Reuters in October, said Air Insulin may have similar effects  on lung function. “We’re assuming that pulmonary insulins in that regard are  all pretty much the same,” he said, although a conclusive  picture of Air Insulin’s safety will not emerge until two-year  safety trials of the product end later this year. A second setback for inhaled insulin came in January, when  Novo Nordisk said it was halting development of its AERx  product, meant to deliver inhaled droplets. The Danish  drugmaker said AERx did not have adequate sales potential,  given the limited commercial success seen with Exubera. Morgan Stanley analyst Jami Rubin said on Friday Lilly’s  abandonment of AIR Insulin made good business sense. “We are not (at) all surprised, and have never been strong  advocates of the pulmonary insulin agents, following the poor  launch and ultimate demise of Pfizer and Nektar’s Exubera and  Novo Nordisk’s termination of its AERx program,” Rubin said in  a research note. Rubin said Alkermes, known for its drug-delivery  technology, is unlikely to continue development of Air Insulin  without Lilly, “given that this represents the third  termination of a pulmonary insulin drug.”    But she said the sharp drop in Alkermes shares represented  a buying opportunity for investors because Air Insulin had only  paltry sales potential. She said investors should be focused instead on another  product Alkermes is developing with Lilly: a long-acting  formulation of Lilly’s Byetta diabetes treatment called Byetta    “We estimate that Byetta LAR could be worth $11 to $12 for  the (Alkermes) stock,” Ryan said. Alkermes shares fell $1.14 to close at $11.26 on Nasdaq. Lilly, a far larger company with an array of big-selling  products, rose 2 cents to end at $49.70 on the New York Stock  Exchange, and was slightly lower at $49.67 in after-hours  trading.

Answer: Eli Lilly drops inhaled insulin program.


Question: The company said the trial will continue unchanged as per the recommendation of a data monitoring committee. The trial was testing Bristol-Myers’ drugs Opdivo and Yervoy, against Opdivo alone, in patients with advanced melanoma. The combination failed to show a statistically significant benefit in patients whose tumors had 1% or lower levels of the PD-L1 protein being targeted, the company said. The American Cancer Society estimates that about 96,480 melanoma cases will be diagnosed in the United States this year. Bristol-Myers shares were trading at $55.99 before the bell.

Answer: Bristol-Myers misses main goal of late-stage skin cancer trial.


Question: The case, published in The Lancet medical journal, involved connecting veins from the donor uterus with the recipient’s veins, as well as linking arteries, ligaments and vaginal canals. It comes after 10 previously known cases of uterus transplants from deceased donors - in the United States, the Czech Republic and Turkey - failed to produce a live birth. The girl born in the Brazilian case was delivered via caesarean section at 35 weeks and three days, and weighed 2,550 grams (nearly 6 lbs), the case study said. Dani Ejzenberg, a doctor at Brazil’s Sao Paulo University hospital who led the research, said the transplant - carried out in September 2016 when the recipient was 32 - shows the technique is feasible and could offer women with uterine infertility access to a larger pool of potential donors. The current norm for receiving a womb transplant is that the organ would come from a live family member willing to donate it. “The numbers of people willing and committed to donate organs upon their own deaths are far larger than those of live donors, offering a much wider potential donor population,” Ejzenberg said in a statement about the results. She added, however, that the outcomes and effects of womb donations from live and deceased donors have yet to be compared, and said the technique could still be refined and optimized. The first baby born after a live donor womb transplant was in Sweden in 2013. Scientists have so far reported a total of 39 procedures of this kind, resulting in 11 live births. Experts estimate that infertility affects around 10 to 15 percent of couples of reproductive age worldwide. Of this group, around one in 500 women have uterine problems. Before uterus transplants became possible, the only options to have a child were adoption or surrogacy. In the Brazilian case, the recipient had been born without a uterus due to a condition called Mayer-Rokitansky-Küster-Hauser syndrome. The donor was 45 and died of a stroke. Five months after the transplant, Ejzenberg’s team wrote, the uterus showed no signs of rejection, ultrasound scans were normal, and the recipient was having regular menstruation. The woman’s previously fertilized and frozen eggs were implanted after seven months and 10 days later she was confirmed pregnant. At seven months and 20 days - when the case study report was submitted to The Lancet - the baby girl was continuing to breastfeed and weighed 7.2 kg (16 lb).

Answer:
World's first baby born via womb transplant from dead donor.